Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,intangibleAssets,capitalSurplus,totalLiab,totalStockholderEquity,otherCurrentLiab,totalAssets,commonStock,retainedEarnings,otherLiab,goodWill,treasuryStock,otherAssets,cash,totalCurrentLiabilities,otherStockholderEquity,propertyPlantEquipment,totalCurrentAssets,longTermInvestments,shortTermInvestments,netReceivables,accountsPayable,deferredLongTermAssetCharges,investments,changeToLiabilities,totalCashflowsFromInvestingActivities,totalCashFromFinancingActivities,changeToOperatingActivities,issuanceOfStock,changeInCash,repurchaseOfStock,effectOfExchangeRate,totalCashFromOperatingActivities,depreciation,changeToAccountReceivables,changeToNetincome,capitalExpenditures,WC,language,region,quoteType,triggerable,quoteSourceName,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,earningsTimestamp,earningsTimestampStart,earningsTimestampEnd,gmtOffSetMilliseconds,esgPopulated,tradeable,currency,marketState,epsTrailingTwelveMonths,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,marketCap,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,shortName,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,exchangeDataDelayedBy,exchange,priceHint,market,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,Shares Short 4,Short Ratio 4,Short % of Float 4,Short % of Shares Outstanding 4,Shares Short (prior month ) 4,Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,compensationRisk,auditRisk,longBusinessSummary,city,phone,state,shareHolderRightsRisk,compensationAsOfEpochDate,governanceEpochDate,boardRisk,country,website,maxAge,overallRisk,address1,industry
t0,GBY.DE,373778000.0,143880992,56434000,,-45677000,-938000,-45933000,16148000,-30154000,-46302000,-46302000,,,,,,262000,26280000,72582000,56434000,1250000,,-45939000,-45933000,55583000.0,1292118000.0,407678000.0,470355000.0,94364000.0,877095000.0,1437000.0,-823914000.0,236376000.0,40994000.0,714000.0,15597000.0,122975000.0,132839000.0,714000.0,115546000.0,606944000.0,42431000.0,464109000.0,7720000.0,11638000.0,,53304000,-23876000,45289000,15235000,-9486000,17469000,-8354000,-2234000,-328000,-68550000,3898000,-1522000,8369000,-7950000,474105000.0,en-US,US,EQUITY,False,Delayed Quote,3.5285723,8.304 - 8.626,8.332,8.542,8.562,finmb_412674,XETRA,"Sangamo Therapeutics, Inc.",USD,855,271,0.9920006,0.12994505,7.634 - 15.668,-7.042,-0.4494511,7.634,15.668,1620144061,1635850740,1636372800,7200000,False,False,EUR,POSTPOST,-0.736,3.273,8.346,0.2800007,0.03354909,9.337422,-0.71142197,-0.076190405,1255514368,2.6355028,15,Europe/Berlin,CEST,"SANGAMO THERAP.INC.DL-,01",8.626,1630510553,0.29400063,8.304,8.626,8.304,33,0,GER,2,de_market,1.73,,,15.67,7.63,8.35,9.34,855,271,143.88M,,119.17M,17.34%,56.10%,,,,,,,,,,,0.00%,,,,,"Dec 31, 2020","Mar 31, 2021",-94.38%,-99.95%,-11.23%,-28.73%,131.4M,0.93,101.00%,-62.45M,-125.09M,-124.02M,-0.74,,587.08M,4.08,42.34M,9.02,4.57,3.27,120.22M,3.86M,Value,94005,Healthcare,413,6,4,"Sangamo Therapeutics, Inc., a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company offers zinc finger protein (ZFP), a technology platform for making zinc finger nucleases, which are proteins used in modifying DNA sequences by adding or knocking out specific genes or genome editing; and ZFP transcription factors proteins used in increasing or decreasing gene expression. It develops SB-525, which is in Phase III AFFINE clinical trial for the treatment of hemophilia A; ST-920, a gene therapy, which is in Phase I/II STAAR clinical trials for the treatment of Fabry disease; BIVV003, a cell therapy, which is in Phase I/II PRECIZN-1 clinical trials for the treatment of sickle cell disease; ST-400, a cell therapy, which is in Phase I/II Thales clinical trials for the treatment of transfusion dependent beta thalassemia. The company also develops TX200, chimeric antigen receptor for the treatment of HLA-A2 mismatched kidney transplant rejection; KITE-037, an anti-CD19 CAR-T cell therapy for the treatment of cancer. ST-101 gene therapy for phenylketonuria. It has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi Genzyme; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was founded in 1995 and is headquartered in Brisbane, California.",Brisbane,510 970 6000,CA,2,1609372800,1622505600,5,United States,http://www.sangamo.com,86400,3,7000 Marina Boulevard,Biotechnology
t-1,GBY.DE,397308000.0,143880992,56434000,,-40567000,-868000,-40604000,16874000,-26558000,-43432000,-43432000,,,,,,108000,25800000,69232000,52358000,2865000,,-40675000,-40604000,58128000.0,1269375000.0,441184000.0,498234000.0,96644000.0,938550000.0,1421000.0,-777981000.0,259241000.0,42798000.0,5419000.0,15057000.0,131329000.0,143547000.0,5419000.0,112369000.0,659668000.0,50530000.0,510094000.0,6259000.0,12553000.0,474000.0,-126246000,-9638000,-130458000,6919000,937000,7111000,-128064000,-192000,-230000,-4295000,3664000,34263000,7083000,-4011000,516121000.0,en-US,US,EQUITY,False,Delayed Quote,3.5285723,8.304 - 8.626,8.332,8.542,8.562,finmb_412674,XETRA,"Sangamo Therapeutics, Inc.",USD,855,271,0.9920006,0.12994505,7.634 - 15.668,-7.042,-0.4494511,7.634,15.668,1620144061,1635850740,1636372800,7200000,False,False,EUR,POSTPOST,-0.736,3.273,8.346,0.2800007,0.03354909,9.337422,-0.71142197,-0.076190405,1255514368,2.6355028,15,Europe/Berlin,CEST,"SANGAMO THERAP.INC.DL-,01",8.626,1630510553,0.29400063,8.304,8.626,8.304,33,0,GER,2,de_market,1.73,,,15.67,7.63,8.35,9.34,855,271,143.88M,,119.17M,17.34%,56.10%,,,,,,,,,,,0.00%,,,,,"Dec 31, 2020","Mar 31, 2021",-94.38%,-99.95%,-11.23%,-28.73%,131.4M,0.93,101.00%,-62.45M,-125.09M,-124.02M,-0.74,,587.08M,4.08,42.34M,9.02,4.57,3.27,120.22M,3.86M,Value,94005,Healthcare,413,6,4,"Sangamo Therapeutics, Inc., a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company offers zinc finger protein (ZFP), a technology platform for making zinc finger nucleases, which are proteins used in modifying DNA sequences by adding or knocking out specific genes or genome editing; and ZFP transcription factors proteins used in increasing or decreasing gene expression. It develops SB-525, which is in Phase III AFFINE clinical trial for the treatment of hemophilia A; ST-920, a gene therapy, which is in Phase I/II STAAR clinical trials for the treatment of Fabry disease; BIVV003, a cell therapy, which is in Phase I/II PRECIZN-1 clinical trials for the treatment of sickle cell disease; ST-400, a cell therapy, which is in Phase I/II Thales clinical trials for the treatment of transfusion dependent beta thalassemia. The company also develops TX200, chimeric antigen receptor for the treatment of HLA-A2 mismatched kidney transplant rejection; KITE-037, an anti-CD19 CAR-T cell therapy for the treatment of cancer. ST-101 gene therapy for phenylketonuria. It has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi Genzyme; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was founded in 1995 and is headquartered in Brisbane, California.",Brisbane,510 970 6000,CA,2,1609372800,1622505600,5,United States,http://www.sangamo.com,86400,3,7000 Marina Boulevard,Biotechnology
t-2,GBY.DE,424858000.0,143880992,56434000,,-1271000,-530000,-1550000,16177000,12476000,-3701000,-3701000,,,,,,237000,57763000,61464000,45287000,2430000,,-1508000,-1550000,55569000.0,1255823000.0,442829000.0,521411000.0,87791000.0,963710000.0,1412000.0,-737377000.0,281009000.0,40984000.0,1553000.0,14183000.0,259393000.0,123561000.0,1553000.0,106919000.0,700294000.0,45761000.0,389434000.0,40309000.0,14456000.0,,-238222000,56438000,-242497000,1616000,2030000,1734000,-208050000,-118000,-236000,33067000,3278000,-33869000,6740000,-4009000,576733000.0,en-US,US,EQUITY,False,Delayed Quote,3.5285723,8.304 - 8.626,8.332,8.542,8.562,finmb_412674,XETRA,"Sangamo Therapeutics, Inc.",USD,855,271,0.9920006,0.12994505,7.634 - 15.668,-7.042,-0.4494511,7.634,15.668,1620144061,1635850740,1636372800,7200000,False,False,EUR,POSTPOST,-0.736,3.273,8.346,0.2800007,0.03354909,9.337422,-0.71142197,-0.076190405,1255514368,2.6355028,15,Europe/Berlin,CEST,"SANGAMO THERAP.INC.DL-,01",8.626,1630510553,0.29400063,8.304,8.626,8.304,33,0,GER,2,de_market,1.73,,,15.67,7.63,8.35,9.34,855,271,143.88M,,119.17M,17.34%,56.10%,,,,,,,,,,,0.00%,,,,,"Dec 31, 2020","Mar 31, 2021",-94.38%,-99.95%,-11.23%,-28.73%,131.4M,0.93,101.00%,-62.45M,-125.09M,-124.02M,-0.74,,587.08M,4.08,42.34M,9.02,4.57,3.27,120.22M,3.86M,Value,94005,Healthcare,413,6,4,"Sangamo Therapeutics, Inc., a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company offers zinc finger protein (ZFP), a technology platform for making zinc finger nucleases, which are proteins used in modifying DNA sequences by adding or knocking out specific genes or genome editing; and ZFP transcription factors proteins used in increasing or decreasing gene expression. It develops SB-525, which is in Phase III AFFINE clinical trial for the treatment of hemophilia A; ST-920, a gene therapy, which is in Phase I/II STAAR clinical trials for the treatment of Fabry disease; BIVV003, a cell therapy, which is in Phase I/II PRECIZN-1 clinical trials for the treatment of sickle cell disease; ST-400, a cell therapy, which is in Phase I/II Thales clinical trials for the treatment of transfusion dependent beta thalassemia. The company also develops TX200, chimeric antigen receptor for the treatment of HLA-A2 mismatched kidney transplant rejection; KITE-037, an anti-CD19 CAR-T cell therapy for the treatment of cancer. ST-101 gene therapy for phenylketonuria. It has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi Genzyme; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was founded in 1995 and is headquartered in Brisbane, California.",Brisbane,510 970 6000,CA,2,1609372800,1622505600,5,United States,http://www.sangamo.com,86400,3,7000 Marina Boulevard,Biotechnology
t-3,GBY.DE,418920000.0,143880992,56434000,,-35965000,-251000,-35929000,17927000,-19970000,-37897000,-37897000,,,,,,0,21553000,59450000,41523000,1932000,,-35965000,-35929000,53219000.0,1247527000.0,383453000.0,511457000.0,61389000.0,894659000.0,1410000.0,-735827000.0,250277000.0,39318000.0,-1653000.0,15314000.0,467443000.0,93942000.0,-1653000.0,107408000.0,679400000.0,,197410000.0,6152000.0,15845000.0,,80764000,188423000,77608000,144156000,-3288000,144200000,381694000,-44000,-63000,159993000,3230000,1352000,6205000,-2919000,585458000.0,en-US,US,EQUITY,False,Delayed Quote,3.5285723,8.304 - 8.626,8.332,8.542,8.562,finmb_412674,XETRA,"Sangamo Therapeutics, Inc.",USD,855,271,0.9920006,0.12994505,7.634 - 15.668,-7.042,-0.4494511,7.634,15.668,1620144061,1635850740,1636372800,7200000,False,False,EUR,POSTPOST,-0.736,3.273,8.346,0.2800007,0.03354909,9.337422,-0.71142197,-0.076190405,1255514368,2.6355028,15,Europe/Berlin,CEST,"SANGAMO THERAP.INC.DL-,01",8.626,1630510553,0.29400063,8.304,8.626,8.304,33,0,GER,2,de_market,1.73,,,15.67,7.63,8.35,9.34,855,271,143.88M,,119.17M,17.34%,56.10%,,,,,,,,,,,0.00%,,,,,"Dec 31, 2020","Mar 31, 2021",-94.38%,-99.95%,-11.23%,-28.73%,131.4M,0.93,101.00%,-62.45M,-125.09M,-124.02M,-0.74,,587.08M,4.08,42.34M,9.02,4.57,3.27,120.22M,3.86M,Value,94005,Healthcare,413,6,4,"Sangamo Therapeutics, Inc., a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company offers zinc finger protein (ZFP), a technology platform for making zinc finger nucleases, which are proteins used in modifying DNA sequences by adding or knocking out specific genes or genome editing; and ZFP transcription factors proteins used in increasing or decreasing gene expression. It develops SB-525, which is in Phase III AFFINE clinical trial for the treatment of hemophilia A; ST-920, a gene therapy, which is in Phase I/II STAAR clinical trials for the treatment of Fabry disease; BIVV003, a cell therapy, which is in Phase I/II PRECIZN-1 clinical trials for the treatment of sickle cell disease; ST-400, a cell therapy, which is in Phase I/II Thales clinical trials for the treatment of transfusion dependent beta thalassemia. The company also develops TX200, chimeric antigen receptor for the treatment of HLA-A2 mismatched kidney transplant rejection; KITE-037, an anti-CD19 CAR-T cell therapy for the treatment of cancer. ST-101 gene therapy for phenylketonuria. It has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi Genzyme; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was founded in 1995 and is headquartered in Brisbane, California.",Brisbane,510 970 6000,CA,2,1609372800,1622505600,5,United States,http://www.sangamo.com,86400,3,7000 Marina Boulevard,Biotechnology
